Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Chief Operating Officer | July 28, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viking Therapeutics, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 440,977 |
Reported balance
After 2026-07-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 31,667 · Balance 440,977 F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal. F2: Includes 120 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan. |
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 422,760 |
Reported balance
After 2026-07-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-29 · Sale · Disposed 18,217 · Balance 422,760 F3: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.28 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.
F2: Includes 120 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan.
F3: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.28 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2023 Filed Apr 3, 2023 23:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0001209191-23-022396 · doc4.xml · derivative · entry 9 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 3,000 shares Expires 2029-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.69 | $0.00 |
DisclosureSEC source: 0001209191-23-022396 · doc4.xml · derivative · entry 8 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: One-third of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 23,100 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0001209191-23-022396 · doc4.xml · derivative · entry 7 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,100 shares Expires 2029-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 30,799 | $17.57 | $541,138.43 |
DisclosureSEC source: 0001209191-23-022396 · doc4.xml · nonDerivative · entry 6 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,763 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 56,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022396 · doc4.xml · nonDerivative · entry 5 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,562 F2 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 66.67% of which vested on April 3, 2023 upon the achievement of two non-financial performance goals. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 36,100 | $17.01 | $614,028.51 |
DisclosureSEC source: 0001209191-23-022396 · doc4.xml · nonDerivative · entry 4 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 3,000 | $6.47 | $19,410.00 |
DisclosureSEC source: 0001209191-23-022396 · doc4.xml · nonDerivative · entry 3 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 10,000 | $7.69 | $76,900.00 |
DisclosureSEC source: 0001209191-23-022396 · doc4.xml · nonDerivative · entry 2 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 23:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 23,100 | $8.52 | $196,812.00 |
DisclosureSEC source: 0001209191-23-022396 · doc4.xml · nonDerivative · entry 1 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · derivative · entry 20 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 41,242 | $16.00 | $659,872.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · nonDerivative · entry 11 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,895 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 15,000 | $9.13 | $136,950.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · nonDerivative · entry 10 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · derivative · entry 19 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2028-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: One-third of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 24,500 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · derivative · entry 18 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,500 shares Expires 2028-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · derivative · entry 17 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · derivative · entry 16 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 53,054 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · derivative · entry 15 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,054 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: 23,054 shares vested on the grant date of 01/05/2017 and 25% of the remaining 30,000 shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · derivative · entry 14 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 4,873 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · derivative · entry 13 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,873 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: The shares subject to the option vested on the grant date. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · derivative · entry 12 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 196,563 | $15.00 | $2,948,445.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · nonDerivative · entry 9 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,137 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 30,000 | $4.37 | $131,100.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · nonDerivative · entry 8 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 484,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 24,500 | $4.65 | $113,925.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · nonDerivative · entry 7 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 454,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 10,000 | $1.04 | $10,400.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · nonDerivative · entry 6 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 15,000 | $1.08 | $16,200.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · nonDerivative · entry 5 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 53,054 | $1.23 | $65,256.42 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · nonDerivative · entry 4 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 405,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 15,000 | $1.26 | $18,900.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · nonDerivative · entry 3 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 4,873 | $1.88 | $9,161.24 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · nonDerivative · entry 2 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 01:04 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 15,000 | $2.15 | $32,250.00 |
DisclosureSEC source: 0001209191-23-021743 · doc4.xml · nonDerivative · entry 1 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 15, 2023 Filed Jan 18, 2023 00:39 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 1,079 | $8.95 | $9,657.05 |
DisclosureSEC source: 0001209191-23-003606 · doc4.xml · nonDerivative · entry 1 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,273 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 04, 2023 Filed Jan 4, 2023 23:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 13,994 | $8.42 | $117,829.48 |
DisclosureSEC source: 0001209191-23-001342 · doc4.xml · nonDerivative · entry 5 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,352 F5 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 204,000 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0001209191-23-001342 · doc4.xml · derivative · entry 6 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Stock · 204,000 shares Expires 2033-01-03 F6 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 18,854 | $8.52 | $160,636.08 |
DisclosureSEC source: 0001209191-23-001342 · doc4.xml · nonDerivative · entry 4 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,346 F5 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 90,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001342 · doc4.xml · nonDerivative · entry 3 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,200 F4 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 23:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 12,773 | $9.40 | $120,066.20 |
DisclosureSEC source: 0001209191-23-001342 · doc4.xml · nonDerivative · entry 2 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,533 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 23:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 23,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001342 · doc4.xml · nonDerivative · entry 1 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,306 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2019, 66.67% of which vested on December 30, 2022 upon the achievement of two non-financial performance goals and a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on December 30, 2022 upon the achievement of a non-financial performance goal. F2 · balance_after: Includes 4,545 shares acquired on May 20, 2022 and 6,566 shares acquired on November 18, 2022 pursuant to the Issuer's 2014 Employee Stock Purchase Plan Read SEC document |
| January 15, 2022 Filed Feb 11, 2022 23:34 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 827 | $4.24 | $3,506.48 |
DisclosureSEC source: 0001209191-22-008999 · doc4.xml · nonDerivative · entry 1 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,695 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:12 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 11,845 | $4.62 | $54,723.90 |
DisclosureSEC source: 0001209191-22-001987 · doc4.xml · nonDerivative · entry 3 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,522 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:12 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 174,000 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-22-001987 · doc4.xml · derivative · entry 4 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,000 Underlying: Common Stock · 174,000 shares Expires 2032-01-03 F4 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:12 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 77,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001987 · doc4.xml · nonDerivative · entry 2 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,367 F3 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:12 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 3,919 | $4.88 | $19,124.72 |
DisclosureSEC source: 0001209191-22-001987 · doc4.xml · nonDerivative · entry 1 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,034 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. F2 · balance_after: Includes 418 shares acquired on November 19, 2021 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 21:45 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 2,839 | $6.50 | $18,453.50 |
DisclosureSEC source: 0001209191-21-058249 · doc4.xml · nonDerivative · entry 2 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,535 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to a performance restricted stock unit award. Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 21:45 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058249 · doc4.xml · nonDerivative · entry 1 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,374 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2020, 33.33% of which vested on September 28, 2021 upon the achievement of a non-financial performance goal. F2 · balance_after: Includes 3,755 shares acquired on May 20, 2021 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| January 19, 2021 Filed Jan 19, 2021 23:23 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 994 | $6.68 | $6,639.92 |
DisclosureSEC source: 0001209191-21-004098 · doc4.xml · nonDerivative · entry 2 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,952 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 23:23 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 686 | $6.48 | $4,445.28 |
DisclosureSEC source: 0001209191-21-004098 · doc4.xml · nonDerivative · entry 1 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,946 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001209191-21-002074 · doc4.xml · derivative · entry 4 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-01-04 F4 · derivative.exercise_date: One-third of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 2,773 | $5.80 | $16,083.40 |
DisclosureSEC source: 0001209191-21-002074 · doc4.xml · nonDerivative · entry 3 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,632 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to a performance restricted stock unit award. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 6,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002074 · doc4.xml · nonDerivative · entry 2 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,405 F2 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 15, 2019, 33.33% of which vested on January 4, 2021 upon the achievement of a non-financial performance goal. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 73,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002074 · doc4.xml · nonDerivative · entry 1 Mancini Marianna · CIK 0001838112 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,655 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.